Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Short Interest Update

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the target of a large increase in short interest in June. As of June 30th, there was short interest totaling 2,154 shares, an increase of ? from the June 15th total of 0 shares. Based on an average trading volume of 101,921 shares, the short-interest ratio is currently 0.0 days.

Ono Pharmaceutical Stock Performance

Shares of OPHLY stock traded up $0.13 on Friday, hitting $4.94. The stock had a trading volume of 17,868 shares, compared to its average volume of 31,939. The business has a 50 day moving average of $4.88 and a 200 day moving average of $4.99. Ono Pharmaceutical has a 12-month low of $3.52 and a 12-month high of $5.75.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty?pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co?developing and commercializing nivolumab (Opdivo), an anti–PD?1 immune checkpoint inhibitor developed in partnership with Bristol?Myers Squibb.